Arcus Operating Margin from 2010 to 2024
| RCUS Stock | USD 15.44 0.36 2.28% |
Check Arcus Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcus Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 41 M, Interest Income of 43 M or Depreciation And Amortization of 6.1 M, as well as many indicators such as Price To Sales Ratio of 11.48, Dividend Yield of 0.0 or PTB Ratio of 3.39. Arcus financial statements analysis is a perfect complement when working with Arcus Biosciences Valuation or Volatility modules.
Arcus | Operating Margin |
Latest Arcus Biosciences' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Arcus Biosciences over the last few years. It is Arcus Biosciences' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcus Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (2.19) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Arcus Operating Margin Regression Statistics
| Arithmetic Mean | (21.66) | |
| Geometric Mean | 9.87 | |
| Coefficient Of Variation | (82.83) | |
| Mean Deviation | 17.23 | |
| Median | (37.82) | |
| Standard Deviation | 17.94 | |
| Sample Variance | 321.99 | |
| Range | 37.9626 | |
| R-Value | 0.88 | |
| Mean Square Error | 80.18 | |
| R-Squared | 0.77 | |
| Significance | 0.000018 | |
| Slope | 3.52 | |
| Total Sum of Squares | 4,508 |
Arcus Operating Margin History
About Arcus Biosciences Financial Statements
Arcus Biosciences shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Arcus Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Arcus Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcus Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 366 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.